JP2012505235A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505235A5
JP2012505235A5 JP2011531168A JP2011531168A JP2012505235A5 JP 2012505235 A5 JP2012505235 A5 JP 2012505235A5 JP 2011531168 A JP2011531168 A JP 2011531168A JP 2011531168 A JP2011531168 A JP 2011531168A JP 2012505235 A5 JP2012505235 A5 JP 2012505235A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently
heterocyclyl
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011531168A
Other languages
English (en)
Japanese (ja)
Other versions
JP5560278B2 (ja
JP2012505235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/059968 external-priority patent/WO2010042699A1/en
Publication of JP2012505235A publication Critical patent/JP2012505235A/ja
Publication of JP2012505235A5 publication Critical patent/JP2012505235A5/ja
Application granted granted Critical
Publication of JP5560278B2 publication Critical patent/JP5560278B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011531168A 2008-10-09 2009-10-08 キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル Expired - Fee Related JP5560278B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10404508P 2008-10-09 2008-10-09
US61/104,045 2008-10-09
PCT/US2009/059968 WO2010042699A1 (en) 2008-10-09 2009-10-08 Imidazopyridazinecarbonitriles useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012505235A JP2012505235A (ja) 2012-03-01
JP2012505235A5 true JP2012505235A5 (enExample) 2012-08-09
JP5560278B2 JP5560278B2 (ja) 2014-07-23

Family

ID=41718919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531168A Expired - Fee Related JP5560278B2 (ja) 2008-10-09 2009-10-08 キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル

Country Status (27)

Country Link
US (3) US8252795B2 (enExample)
EP (1) EP2350081B1 (enExample)
JP (1) JP5560278B2 (enExample)
KR (1) KR20110075010A (enExample)
CN (1) CN102245609B (enExample)
AR (1) AR073818A1 (enExample)
AU (1) AU2009302360B2 (enExample)
BR (1) BRPI0920135A2 (enExample)
CA (1) CA2739782A1 (enExample)
CL (1) CL2011000777A1 (enExample)
CO (1) CO6361936A2 (enExample)
CY (1) CY1114539T1 (enExample)
DK (1) DK2350081T3 (enExample)
EA (1) EA018163B1 (enExample)
ES (1) ES2426951T3 (enExample)
HR (1) HRP20130787T1 (enExample)
IL (1) IL211693A (enExample)
MX (1) MX2011003304A (enExample)
NZ (1) NZ591712A (enExample)
PE (1) PE20110411A1 (enExample)
PL (1) PL2350081T3 (enExample)
PT (1) PT2350081E (enExample)
SI (1) SI2350081T1 (enExample)
SM (1) SMT201300109B (enExample)
TW (1) TWI491610B (enExample)
WO (1) WO2010042699A1 (enExample)
ZA (1) ZA201102423B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
US9284317B2 (en) 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080232A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
CA2914745A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CA3028727A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals, Inc. Ck2 inhibitors, compositions and methods thereof
PL3498693T3 (pl) * 2016-08-10 2025-03-24 Takeda Pharmaceutical Company Limited Związek heterocykliczny
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
WO2019081486A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2019128871A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
BR112020013313B1 (pt) 2017-12-29 2023-10-31 Jiangsu Flag Chemical Industry Co., Ltd Composto de pirazolamida de fórmula geral i, composto de fórmula ii, método para preparar um composto de fórmula geral i, uso do composto de fórmula geral i, composição inseticida e método para controlar pragas
CN109988150B (zh) 2017-12-29 2022-04-12 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
AU2019212969B2 (en) * 2018-01-29 2025-01-23 Merck Patent Gmbh GCN2 inhibitors and uses thereof
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
KR102865925B1 (ko) * 2019-03-05 2025-09-26 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
KR20220002890A (ko) 2019-03-19 2022-01-07 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 아자-벤조티오펜 및 아자-벤조푸란 화합물
US12403135B2 (en) 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CA3137610A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
KR102915019B1 (ko) 2019-04-24 2026-01-21 바이엘 악티엔게젤샤프트 4H-피롤로[3,2-c]피리딘-4-온 화합물
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
BR112022024156A2 (pt) 2020-05-29 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Compostos heterocílicos antelmínticos
AU2022216415A1 (en) * 2021-02-03 2023-09-21 Sanofi DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2023073641A1 (en) 2021-11-01 2023-05-04 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds
AU2023212957A1 (en) * 2022-01-25 2024-08-22 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
WO2024039767A1 (en) * 2022-08-18 2024-02-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases
CN115947756B (zh) * 2022-12-13 2025-08-01 西湖大学 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
CA2551867C (en) * 2003-12-31 2010-08-17 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑－类抑制剂
JPWO2006070943A1 (ja) * 2004-12-28 2008-06-12 武田薬品工業株式会社 縮合イミダゾール化合物およびその用途
US20070185063A1 (en) 2005-08-23 2007-08-09 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008016192A2 (en) * 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1911451A1 (en) * 2006-10-10 2008-04-16 INSERM (Institut National de la Santé et de la Recherche Medicale) Protein-kinase CK2 inhibitors and their therapeutic applications
US20090318410A1 (en) * 2006-10-30 2009-12-24 Novartis Ag Imidazopyridazines as lipid kinase inhibitors
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009100375A1 (en) * 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Similar Documents

Publication Publication Date Title
JP2013523756A5 (enExample)
JP2011511095A5 (enExample)
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2019518766A5 (enExample)
RU2020102453A (ru) Фармацевтические композиции
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
HRP20131051T1 (hr) Inhibitori proteinskih kinaza
JP2010510215A5 (enExample)
JP2019512478A5 (enExample)
JP2012153722A5 (enExample)
NZ710745A (en) Pyrrolobenzodiazepines and conjugates thereof
JP2005524631A5 (enExample)
JP2017531041A5 (enExample)
JP2017511321A5 (enExample)
JP2014533299A5 (enExample)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2014507421A5 (enExample)
HK1208217A1 (en) Pyrrolobenzodiazepines
JP2013520424A5 (enExample)
JP2021534097A5 (enExample)
JP2009542683A5 (enExample)
JP2013538213A5 (enExample)
JP2016503414A5 (enExample)
JP2013528619A5 (enExample)
JP2013199483A5 (enExample)